You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

Article metrics

Article menu

Download PDFPDF

Oral Presentation
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
Free

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 2019040
Jan 2020010
Feb 2020071
Mar 2020091
Apr 2020071
May 20200112
Jun 20200281
Jul 202001610
Aug 2020070
Sep 2020070
Oct 2020063
Nov 20200125
Dec 20200143
Jan 2021033
Feb 20210224
Mar 2021093
Apr 2021092
May 20210175
Jun 20210191
Jul 20210183
Aug 2021085
Sep 20210133
Oct 2021052
Nov 20210145
Dec 20210491
Jan 20220200
Feb 20220193
Mar 20220166
Apr 20220237
May 20220112
Jun 20220258
Jul 20220121
Aug 20220167
Sep 20220214
Oct 20220203
Nov 202203112
Dec 20220208
Jan 20230212
Feb 20230142
Mar 20230274
Apr 20230207
May 2023073
Jun 20230152
Jul 20230178
Aug 20230162
Sep 20230104
Oct 20230222
Nov 20230296
Dec 20230594
Jan 20240334
Feb 20240325
Mar 202405410
Total0925190